Welcome

Welcome to the website for Transregional Collaborative Research Center (CRC) SFB TR-128 Initiating/effector versus regulatory mechanisms in Multiple Sclerosis – progress towards tackling the disease. On this site you will find general information regarding the CRC as well as more specific information about its individual research projects.

Multiple Sclerosis (MS) is the most common chronic inflammatory disease of the central nervous system (CNS) in the western world and it leads to devastating disability in young adults, with only limited treatment options currently available. The socioeconomic burden of this disease is tremendous, since healthcare costs are very high and it affects decisions young patients must make for the rest of their lives. Findings in patients are a complex composite of inflammation (with demyelination, remyelination, axonal/neuronal damage) typically in subcortical, but also cortical, disseminated lesions as well as neurodegeneration. Remissions of clinical relapses point to repair capacities of the CNS, which exhibits strong interindividual and course dependent differences.

Heinz Wiendl
Spokesperson

Frauke Zipp
Co-Spokesperson

News

Mon, 20/09/2021
Register now: 1st Symposium inflammation and imaging
When?: from November 2nd to November 4th 2021 Where?: Schloss (seat of the University Administration) Muenster Organizers: Co-operative Research Centres 1009, 1450, Transregio 128, and Clinical Research Unit 342 – together with Interdisciplinary Centre of Clinical Research (IZKF) and Excellence Cluster Cells in Motion (CiM) Registration is open now! More information: here...more
Mon, 09/08/2021
Dietary conjugated linoleic acid links reduced intestinal inflammation to amelioration of CNS autoimmunity
A close interaction between gut immune responses and distant organ-specific autoimmunity including the CNS in multiple sclerosis has been established in recent years. This so-called gut-CNS axis can be shaped by dietary factors, either directly or via indirect modulation of the gut microbiome and its metabolites. Here, SFB 128 PI Luisa Klotz and colleagues report […]...more
Thu, 28/01/2021
BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science
BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced the publication of preclinical data on its novel mRNA vaccine approach against autoimmune diseases in the peer-reviewed journal Science. The publication titled “A non-inflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis” co-authored by SFB principal investigator Ari Waisman summarizes the findings on the disease-suppressing effects […]...more